Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Accounts Payables (2016 - 2025)

Lineage Cell Therapeutics' Accounts Payables history spans 16 years, with the latest figure at $7.2 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 511.67% year-over-year to $7.2 million; the TTM value through Dec 2025 reached $7.2 million, up 511.67%, while the annual FY2025 figure was $7.2 million, 511.67% up from the prior year.
  • Accounts Payables reached $7.2 million in Q4 2025 per LCTX's latest filing, up from $1.5 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $28.0 million in Q4 2021 to a low of $1.2 million in Q4 2024.
  • Average Accounts Payables over 5 years is $4.8 million, with a median of $2.9 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: soared 971.2% in 2021, then tumbled 91.44% in 2022.
  • A 5-year view of Accounts Payables shows it stood at $28.0 million in 2021, then crashed by 91.44% to $2.4 million in 2022, then decreased by 14.33% to $2.0 million in 2023, then tumbled by 42.73% to $1.2 million in 2024, then soared by 511.67% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Accounts Payables are $7.2 million (Q4 2025), $1.5 million (Q3 2025), and $4.5 million (Q2 2025).